← All trials
NCT06038539
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2023
- Primary completion
- Feb 15, 2026
- Completion date
- Oct 15, 2026
- First posted
- Sep 15, 2023
- Last posted
- Sep 25, 2023
- Enrollment
- 382
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biocon LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.